Detalhe da pesquisa
1.
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.
J Clin Med
; 10(16)2021 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34442045